First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Jeffrey S. Miller, Michael R. Verneris et al.|Blood|2018Cited by 406
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell LymphomasMaximillian Rosario, Todd A. Fehniger, Bai Liu et al.|Clinical Cancer Research|2015Cited by 147